Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment ...
Latest long-term analysis, including more than three years of follow-up data of patients with Grade 2 IDH-mutant glioma treated with VORANIGO® (vorasidenib), will be presented in a rapid oral session on May 31 at 4:36 p.m. CDT Results show median …